169 related articles for article (PubMed ID: 26456240)
41. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
42. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
43. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
44. Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells.
Lee H; Park S; Kim JB; Kim J; Kim H
Cancer Lett; 2013 May; 332(1):110-9. PubMed ID: 23348696
[TBL] [Abstract][Full Text] [Related]
45. Microfluidic-enabled self-organized tumor model for in vitro cytotoxicity assessment of doxorubicin.
Yang Y; Liu S; Chen C; Huang H; Tao L; Qian Z; Li W
Biomed Microdevices; 2020 Sep; 22(4):70. PubMed ID: 32960346
[TBL] [Abstract][Full Text] [Related]
46. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
47. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production.
Chorna I; Bilyy R; Datsyuk L; Stoika R
Exp Oncol; 2004 Jun; 26(2):111-7. PubMed ID: 15273662
[TBL] [Abstract][Full Text] [Related]
48. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
Lee ES; Na K; Bae YH
J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
[TBL] [Abstract][Full Text] [Related]
49. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
[TBL] [Abstract][Full Text] [Related]
50. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
51. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
52. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
53. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
54. Microfluidic cell isolation technology for drug testing of single tumor cells and their clusters.
Bithi SS; Vanapalli SA
Sci Rep; 2017 Feb; 7():41707. PubMed ID: 28150812
[TBL] [Abstract][Full Text] [Related]
55. Parallel probing of drug uptake of single cancer cells on a microfluidic device.
Yang Y; Le Gac S; Terstappen LW; Rho HS
Electrophoresis; 2018 Feb; 39(3):548-556. PubMed ID: 29193175
[TBL] [Abstract][Full Text] [Related]
56. Construction of single-cell arrays and assay of cell drug resistance in an integrated microfluidic platform.
Pang L; Liu W; Tian C; Xu J; Li T; Chen SW; Wang J
Lab Chip; 2016 Nov; 16(23):4612-4620. PubMed ID: 27785515
[TBL] [Abstract][Full Text] [Related]
57. Drug screening of cancer cell lines and human primary tumors using droplet microfluidics.
Wong AH; Li H; Jia Y; Mak PI; Martins RPDS; Liu Y; Vong CM; Wong HC; Wong PK; Wang H; Sun H; Deng CX
Sci Rep; 2017 Aug; 7(1):9109. PubMed ID: 28831060
[TBL] [Abstract][Full Text] [Related]
58. An Integrated Microfluidics Approach for Personalized Cancer Drug Sensitivity and Resistance Assay.
Desyatnik I; Krasner M; Frolov L; Ronen M; Guy O; Wasserman D; Tzur A; Avrahami D; Barbiro-Michaely E; Gerber D
Adv Biosyst; 2019 Nov; 3(11):e1900001. PubMed ID: 32648689
[TBL] [Abstract][Full Text] [Related]
59. Biomimetic artificial cells to model the effect of membrane asymmetry on chemoresistance.
Stephenson EB; Elvira KS
Chem Commun (Camb); 2021 Jul; 57(53):6534-6537. PubMed ID: 34106114
[TBL] [Abstract][Full Text] [Related]
60. A microchip for integrated single-cell genotoxicity assay.
Dong H; Sun H; Zheng J
Talanta; 2016 Dec; 161():804-811. PubMed ID: 27769486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
